Broncopneumopatia cronica ostruttiva (BPCO)

  • C. Terzano
  • A. Petroianni


La broncopneumopatia cronica ostruttiva (BPCO) è una delle maggiori cause di morbilità e mortalità in tutto il mondo. A causa dell’elevata prevalenza e della possibilità di essere una patologia altamente invalidante, i costi della BPCO possono rappresentare un importante impegno economico e sociale per la spesa sanitaria.

Letture consigliate

  1. Allegra L, Blasi F, de Bernardi B et al (2001) Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 14:149–155PubMedCrossRefGoogle Scholar
  2. American Thoracic Society (1991) Lung function testing: selection of reference value and interpretative strategies. Am Rev Respir Dis 144:1202–1218Google Scholar
  3. American Thoracic Society (1996) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152:S1–S120Google Scholar
  4. Anthonisen NR, Manfreda J, Warren CP et al (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med 106:196–120PubMedGoogle Scholar
  5. Anthonisen NR, Connett JE, Kiley JP et al (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272:1497–1505PubMedCrossRefGoogle Scholar
  6. Auerbach O, Hammond EC, Garfinkel L, Benante C (1972) Relation of smoking and age to emphysema. Whole-lung section study. N Engl J Med 286:853–857PubMedGoogle Scholar
  7. Ayres JG, Price MJ, Efthimiou J (2003) Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomised, placebo-controlled trial. Respir Med 97:212–220PubMedCrossRefGoogle Scholar
  8. Baldi S, Miniati M, Bellina CR et al (2001) Relationship between extent of pulmonary emphysema by High-resolution Computed Tomography and lung elastic recoil in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 164:585–589PubMedGoogle Scholar
  9. Bellia V, Pistelli R, Catalano F et al (2000) Quality control of spirometry in the elderly. The SARA Study. Am J Respir Crit Care Med 161:1094–1100PubMedGoogle Scholar
  10. Bestall JC, Paul EA, Garrod R et al (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54:581–586PubMedGoogle Scholar
  11. Bourbeau J (2003) Inhaled corticosteroids and survival in chronic obstructive pulmonary disease. Eur Respir J 21:202–203PubMedCrossRefGoogle Scholar
  12. Boushey HA (1999) Glucocorticoid therapy for Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1990–1991PubMedCrossRefGoogle Scholar
  13. Burge PS, Calverley PMA, Jones PW et al (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320:1297–1303PubMedCrossRefGoogle Scholar
  14. Calverley PMA (2002) Medical therapy for COPD: lessons from the real world. Eur Respir J 20:797–798PubMedCrossRefGoogle Scholar
  15. Celli BR, Snider GL, Heffner J (1995) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152:S77–S121Google Scholar
  16. Cosio MG, Guerassimov A (1999) Chronic Obstructive Pulmonary Disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 160:S21–S25PubMedGoogle Scholar
  17. Cosio MG, Majo J, Cosio MG (2002) Inflammation of the airways and lung parenchyma in COPD. Role of T cells. Chest 121:160S–165SPubMedCrossRefGoogle Scholar
  18. Dorinsky PM, Reisner C, Ferguson GT et al (1999) The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 115:966–971PubMedCrossRefGoogle Scholar
  19. Eller J, Ede A, Shaberg T et al (1998) Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 113:1542–1548PubMedGoogle Scholar
  20. Epstein PE (2003) Inhaled corticosteroids and chronic obstructive pulmonary disease: are we barking up the wrong tracheobronchial tree? Ann Intern Med 138:1001–1002PubMedGoogle Scholar
  21. Faber JP, Poller W, Olek K et al (1993) The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J Hepatol 18:313–321PubMedCrossRefGoogle Scholar
  22. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG (1995) Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 152:1666–1672PubMedGoogle Scholar
  23. Fletcher EC, Peto R (1997) The natural history of chronic airflow obstruction. Br Med J 1:1645–1648Google Scholar
  24. Global Initiative for Chronic Obstructive Lung Disease (1998) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop reportGoogle Scholar
  25. Hajiro T, Nishimura K, Tsukino M et al (2000) Stage of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med 94:841–846PubMedCrossRefGoogle Scholar
  26. Harrison DJ, Cantlay AM, Rae F et al (1997) Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol 16:356–360PubMedCrossRefGoogle Scholar
  27. Highland KB, Strange C, Heffner JE (2003) Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. Ann Intern Med 138:969–973PubMedGoogle Scholar
  28. Holtzman MJ, Morton JD, Shornick LP et al (2001) Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. Physiol Rev 82:19–46Google Scholar
  29. Humerfelt S, Gulsvik A, Skjaerven R et al (1993) Decline in FEV1 and airflow limitation related to occupational exposures in men of an urban community. Eur Respir J 6:1095–1103PubMedGoogle Scholar
  30. Irwin RS, Madison JM (2003) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 348:2679–2681PubMedCrossRefGoogle Scholar
  31. Jones PW, Willits LR, Burge PS et al (2003) Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21:68–73PubMedCrossRefGoogle Scholar
  32. Kerstjens HAM (1999) Clinical evidence stable chronic obstructive pulmonary disease. BMJ 319:495–500PubMedGoogle Scholar
  33. Kesten S, Chapman KR (1993) Physician perceptions and management of COPD. Chest 104:254–258PubMedCrossRefGoogle Scholar
  34. Khoury MJ, Beaty TH, Newill CA et al (1986) Genetic-environmental interactions in chronic airways obstruction. Int J Epidemiol 15:65–72PubMedCrossRefGoogle Scholar
  35. Knighton DR, Hunt TK, Scheuenstuhl H et al (1983) Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 221:1283–1285PubMedCrossRefGoogle Scholar
  36. Lane DJ, Howell JB, Giblin B (1968) Relation between airways obstruction and CO2 tension in chronic obstructive airways disease. BMJ 3:707–709PubMedGoogle Scholar
  37. Laurell CB, Eriksson S (1963) The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest 15:132–140CrossRefGoogle Scholar
  38. Leuenberger P, Schwartz J, Ackermann-Liebrich U et al (1994) Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 150:1222–1228PubMedGoogle Scholar
  39. McKeever TM, Scrivener S, Broadfield M et al (2002) Prospective study of diet and decline in lung function in a general population. Am J Respir Crit Care Med 165:1299–1303PubMedCrossRefGoogle Scholar
  40. Murray CJL, Lopez AD (1996) Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274:740–743PubMedCrossRefGoogle Scholar
  41. Niedermann MS (2000) Infection and antibiotic treatment in acute exacerbations of chronic bronchitis. In Allegra L, Blasi F (eds) Mechanisma and Management of COPD exacerbations. Sprnger Verlag Italia, Milano, pp 73–87Google Scholar
  42. Niewoehner DE, Erbland ML, Deupree RH et al (1999) Effect of systemic glucocorticoids on exacerbations of Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1941–1947PubMedCrossRefGoogle Scholar
  43. O’Donnell DE, Forkert L, Webb KA (2001) Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J 18:914–920PubMedCrossRefGoogle Scholar
  44. O’Donnell DE, Lam M, Webb KA (1999) Spirometric correlates of improvement in exercise performance after anticholinergic therapy in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 160:542–549PubMedGoogle Scholar
  45. O’Donnell DE (2000) Assessment of bronchodilator efficacy in symptomatic COPD. Chest 117:42S–47SPubMedCrossRefGoogle Scholar
  46. Paggiaro PL, Dahle R, Bakran I et al (1998) Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351:773–780PubMedCrossRefGoogle Scholar
  47. Pauwels RA, Lofdhal CG, Aitinen AA et al (1999) Long-term treatment with inhaled budesonide in persons with mild Chronic Obstructive Pulmonary Disease who continue smoking. N Engl J Med 340:1948–1953PubMedCrossRefGoogle Scholar
  48. Prescott E, Lange P, Vestbo J (1999) Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 13:1109–1114PubMedCrossRefGoogle Scholar
  49. Repine JE, Bast A, Lankhorst I (1997) Oxidative stress in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 156:341–357PubMedGoogle Scholar
  50. Saetta M, Turato G, Maestrelli P (2001) Cellular and structural bases of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 163:1304–1309PubMedGoogle Scholar
  51. Santus P, Pecchiari M, Carlucci P et al (2003) Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. Eur Respir J 21:82–85PubMedGoogle Scholar
  52. Schols AM, Soeters PB, Dingemans AM et al (1993) Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 147:1151–1156PubMedGoogle Scholar
  53. Siafakas NM, Tzortzaki EG, Sourvinos G et al (1999) Microsatellite DNA instability in COPD. Chest 116:47–51PubMedCrossRefGoogle Scholar
  54. Sin DD, Man SFP (2003) Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 21:260–266PubMedCrossRefGoogle Scholar
  55. Smith CA, Harrison DJ (1997) Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630–633PubMedCrossRefGoogle Scholar
  56. Soriano JB, Vestbo J, Pride NB et al (2002) Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20:819–825PubMedCrossRefGoogle Scholar
  57. Tager IB, Segal MR, Speizer FE, Weiss ST (1988) The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 138:837–849PubMedGoogle Scholar
  58. Terzano C, Mannino F (1997) Aerosol-Caratteristiche, analisi, applicazioni terapeutiche. McGraw-Hill, MilanoGoogle Scholar
  59. Terzano C (1999) Applicazioni mediche degli aerosol: dalla fisiopatologia all’azione terapeutica. Momento Medico, SalernoGoogle Scholar
  60. Terzano C, Petroianni A, Ricci A, Allegra L (2005) Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters. Eur Rev Med Pharmacol Sci 9:209–215PubMedGoogle Scholar
  61. Terzano C, Allegra L (2002) Importance of drug delivery system in steroid aerosol therapy via nebulizer. Pulm Pharmacol Ther 15:449–454PubMedCrossRefGoogle Scholar
  62. The COPD Guidelines Group of the Standards of Care Committee of the BTS (1997) Guidelines for the management of chronic obstructive pulmonary disease. Thorax 52:S1–S28CrossRefGoogle Scholar
  63. The Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in Chronic Obstructive Pulmonary Disease. N Engl J Med 343:1902–1909CrossRefGoogle Scholar
  64. Turato G, Zuin R, Saetta M (2001) Pathogenesis and pathology of COPD. Respiration 68:117–128PubMedCrossRefGoogle Scholar
  65. Van Balkom, RHH, Zhan WZ et al (1997) Corticosteroid effects on isotonic contractile properties of rat diaphragm muscle. J Appl Physiol 83:1062–1067PubMedGoogle Scholar
  66. van Noord JA, de Munck DRAJ, Bantje TA (2000) Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 15:878–885PubMedCrossRefGoogle Scholar
  67. Vestbo J, Sørensen T, Lange P (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353:1819–1823PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • C. Terzano
    • 1
    • 2
  • A. Petroianni
    • 3
  1. 1.Malattie dell’Apparato RespiratorioUniversità degli Studi “La Sapienza”Roma
  2. 2.UOC Malattie RespiratorieAzienda Policlinico Umberto IRoma
  3. 3.UOC Malattie Respiratorie, Azienda Policlinico Umberto IUniversità degli Studi “La Sapienza”Roma

Personalised recommendations